Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. ARTV
8. AAPL
9. SSD
10. BA

Go back to Biohaven Pharma (BHVN) Reports Q2, Provides Update on Recent Business Developments

Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments

July 31, 2023 6:59 AM EDT

Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disordersBrain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to dateBiohaven anticipates initiating a Phase 2 clinical trial in Parkinson's disease and... More